Lexicon Pharmaceuticals (LXRX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.06
- Estimate
- -$0.05
- Surprise
- -24.8%
- Revenue (period 2026-06-30)
- $692,000
- Score today
- 4.1/10
Revenue source: xbrl.
How the report landed
Lexicon Pharmaceuticals (LXRX) reported adjusted EPS of -$0.06, in line with the -$0.05 estimate.
Where TrendMatrix's rating stands now
TrendMatrix currently rates LXRX Sell at 4.1/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -24.8% surprise compares with a +39.6% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Product: INPEFA (sotagliflozin)
- Concentration risk — Supplier: sole-source drug product manufacturer (INPEFA)
- DATA_ISSUE: analyst_target_implausible (raw $4.46 vs price $1.46 — ratio 3.1×). Rejected, falling back to technical TP.
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $1.46
- Price target
- $1.91
- Stop
- $1.35
- Upside to target
- +31.3%
Risk check: RSI 24 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-10-27 — shown for context, not personalized investment advice.
LXRX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $645.2M
- P/E (fwd)
- -7.6
- 52-week range
- $1.10–$2.68
- Off 52-week high
- 45.7%
- RSI (14)
- 24
- Volume vs avg
- 0.15×
- Score today
- 4.1/10